Impaired autophagy flux contributes to enhanced ischemia reperfusion injury in the diabetic heart-Reference-Cited by-同舟云学术

Impaired autophagy flux contributes to enhanced ischemia reperfusion injury in the diabetic heart

Published:2024-03-21 Issue:1 Volume:3 Page:
ISSN:2769-4127
Container-title:Autophagy Reports
language:en
Short-container-title:Autophagy Reports

Author:

Tang Jialing¹,Yoon Nanyoung¹,Dadson Keith¹,Sung Hye Kyoung¹,Lei Yubin¹,Dang Thanh Q.¹,Chung Wing Yan¹,Ahmed Saher¹,Abdul-Sater Ali A.²,Wu Jun³,Li Ren-Ke³,Jonkman James⁴,McKee Trevor⁵,Grant Justin⁵⁶,Peterson Jeffrey D.⁷,Sweeney Gary¹^ORCID

Affiliation:

1. Department of Biology, York University, Toronto, Ontario, Canada

2. School of Kinesiology and Health Science, York University, Toronto, Canada

3. Division of Cardiovascular Surgery and Toronto General Research Institute, University Health Network, Toronto, Canada

4. Advanced Optical Microscopy Facility (AOMF), University Health Network, Toronto, Canada

5. Spatio-temporal Targeting and Amplification of Radiation Response (STTARR), Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

6. Faculty of Pharmacy, University of Toronto, Toronto, Ontario

7. Revvity, Inc Life Science and Technology, Hopkinton, MA, USA

Funder

Canadian Institutes of Health Research

Heart and Stroke Foundation of Canada

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/27694127.2024.2330327

Reference70 articles.

1. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update;Dunlay SM;Circulation

2. Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus;Rawshani A;Circulation

3. Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus;Sousa GR;Circulation

4. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus;Figtree GA;Circulation

5. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial;Cosentino F;Circulation